摘要
目的 探讨P38丝裂原活化蛋白激酶(P38MAPK)在促红细胞生成素(EPO)后处理减轻缺血/再灌注损伤大鼠肺细胞凋亡中的作用。方法 雄性SD大鼠随机分成5组(n=8),即对照组(C组)、肺缺血/再灌注组(I/R组)、肺缺血/再灌注+促红细胞生成素组(促红细胞生成素组)、促红细胞生成素+溶剂对照组(D组)、促红细胞生成素+SB203580组(SB组)。分别于再灌注2 h颈动脉取血、留取左肺组织,检测血清超氧化物歧化酶(SOD)、丙二醛(MDA)、髓过氧化物酶(MPO),光镜观察肺组织形态学结构改变,并进行肺组织损伤定量评估(IQA);原位末端标记法(TUNEL)检测肺细胞凋亡情况并计算凋亡指数(AI)。结果 与对照组相比,肺缺血/再灌注组血清超氧化物歧化酶活性显著降低,丙二醛含量、髓过氧化物酶活力显著升高(P<0.01),肺组织损伤定量评估和凋亡指数均显著升高(P<0.05或P<0.01),光镜下肺组织结构发生明显损伤;促红细胞生成素组、促红细胞生成素+溶剂对照组、SB203580组与肺缺血/再灌注组相比,丙二醛含量、髓过氧化物酶活力显著降低,超氧化物歧化酶活性升高(P<0.05或P<0.01),肺组织损伤定量评估和凋亡指数均显著降低(P<0.05或P<0.01),光镜下肺组织结构损伤情况有所改善;促红细胞生成素+溶剂对照组与促红细胞生成素组比较各项指标均无明显差异(P均>0.05);SB203580组与促红细胞生成素组相比,丙二醛含量、髓过氧化物酶活力显著降低,超氧化物歧化酶活性升高(P<0.05或P<0.01),肺组织损伤定量评估和凋亡指数均显著降低(P<0.05或P<0.01),光镜下肺组织结构未见明显损伤。结论 促红细胞生成素可以通过减轻肺组织过度氧化应激,肺内中性粒细胞聚集,抑制P38丝裂原活化蛋白激酶激活,改善I/R引起的肺组织结构破坏和肺细胞凋亡。
Abstract
OBJECTIVE To investigate the effects of P38MAPK on erythropoietin (EPO) postconditioning attenuating pneumocyte apoptosis after lung ischemia/reperfusion injury(LIRI) in rats. METHODS Adult male Sprague-Dawley rats were randomly divided into 5 groups based upon the intervention (n=8):control group (C), LIRI group (I/R), LIRI+EPO group(EPO), EPO+solution countrl group(D), EPO+SB203580 group(SB). At the end of the experiment, blood specimens drawn from the arteria carotis were tested for the content of malondialdehyde (MDA), the activity of superoxide dismutase (SOD)and myeloperoxidase (MPO). The histological structure of the left lung was observed under light microscope, and scored by alveolar damage index of quantitative assessment (IQA). The pneumocyte apoptosis index(AI) was achieved by terminal deoxynucleotidyl transferase mediated dUTP nick end abeling (TUNEL). RESULTS Compared with C group, in I/R group IQA,AI and MDA level, MPO activity were significantly increased, SOD activity was reduced(P<0.05 or P<0.01), and morphological abnormality occurred in lung tissue. Compared with I/R group, IQA,AI and MDA level, MPO activity were significantly decreased, SOD activity was improved (P<0.05 or P<0.01), and morphological abnormality in lung tissue was obviously reduced in EPO, D and SB groups. There were no siginificant difference in all of the indexes between D and EPO groups(P>0.05). However, compared with EPO group, SOD activity was increased(P<0.05 or P<0.01), the other indexes were obviously reduced, and the abnormal changes of the morphology in I/R were also improved markedly in SB group. CONCLUSION EPO may attenuate pneumocyte apoptosis in LIRI by reducing oxidant generation, neutrophils filtration , then inhibiting activation of P38MAPK
关键词
缺血/再灌注 /
促红细胞生成素 /
超氧化物歧化酶 /
丙二醛 /
髓过氧化物酶 /
细胞凋亡 /
P38MAPK
{{custom_keyword}} /
Key words
ischemia/reperfusion injury /
erythropoietin /
SOD /
MDA /
MPO /
cell apoptosis /
P38MAPK
{{custom_keyword}} /
陈海娥,金晓盛,宋冬,何金波,应磊,游昕*,王万铁*.
P38丝裂原活化蛋白激酶在促红细胞生成素后处理减轻再灌注损伤肺细胞凋亡中的作用[J]. 中国药学杂志, 2014, 49(10): 833-836 https://doi.org/10.11669/cpj.2014.10.010
CHEN Hai-e,JIN Xiao-sheng,SONG Dong, HE Jin-bo,YING Lei,YOU Xin*,WANG Wan-tie*.
Effects of P38MAPK on Erythropoietin Postconditioning Attenuating Pneumocyte Apoptosis after Lung Ischemia/Reperfusion Injury[J]. Chinese Pharmaceutical Journal, 2014, 49(10): 833-836 https://doi.org/10.11669/cpj.2014.10.010
中图分类号:
R363
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] NIE J,LI J S,WANG J J. Mechanisms and progress of prevention of the lung ischemia-reperfusion injury. Int J Transpl Hemopur(国际移植与血液净化杂志),2007, 5(3):20-25.[2] CHEN B X,REN P. The progress of signaling molecules P38MAPK in myocardial ischemia reperfusion injury. J Cardiovas Pulm Dis(心肺血管病杂志),2010, 29 (1):68-70.[3] WANG J,ZUO Q L,XU H R,et al. The role of p38MAPK in focal cerebral ischemia/reperfusion injury in rats. J Clin Med Pract(实用临床医药杂志),2011, 15(13):5-7,11.[4] ZHENG Y R,SHI L,WANG W T,et al. Effect of SB203580 on cell apoptosis during lung ischemia/reperfusion injury in rats. Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2009, 14(11):1242-1246.[5] LEI D H,YIN Y S. Research progress of the erythropoietin′s potential cytoprotective effects. Youjiang Med J(右江医学),2009,37:340-342.[6] YI S H. Protective activity of human erythropoietin against renal ischemia-reperfusion injury. Immunol J(免疫学杂志), 2007, 23(1):49-51.[7] SPANDOU E, TSOUCHNIKAS I, KARKAVELAS G. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. . Nephrology Dialysis Transplantation, 2006, 21(2):330-336.[8] ZHOU Y, DING F. Progress of the erythropoietin′s clinical applications. Shanghai Med Pharm J(上海医药), 2009, 30:297-300.[9] MOON C, KRAWCZYK M, AHN D,et al. Erythropoietin reduces myocardial infarction and leftventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci, 2003, 100(20):11612-11617.[10] ALTUNKAYA A, ESER O Z, SIVRIKOZ M C,et al. Role of nitric oxide pathway in ischemia-reperfusion injury in isolated perfused guinea pig lungs. Mol Cell Biochem, 2006, 290 (1-2):9-16.[11] ZHANG X. Research advances on superoxide dismutase(SOD). Inner Mongolia Petrochem(内蒙古石油化工), 2010, 16:14-15.[12] MCMILLEN M A, HURIBAL M, SUNPIO B. Common pathway of endothelial-leukocyte interaction in shock, ishemia and reperfusion. Am J Surg, 1993,166 (5):557-562.[13] SUN X L. The activity changes and its significance of Mitogen-activated protein kinase P38 pathway in renal ischemia-reperfusion injury. J Shanxi Med Univ(山西医科大学学报), 2002, 33(4):382-384.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
全军医药卫生科研项目(10MA052);浙江省中医药重点学科建设计划(2012-XK-A28);温州市科技计划一般项目(Y20120001)
{{custom_fund}}